382 related articles for article (PubMed ID: 25695332)
1. Human immunodeficiency virus-negative plasmablastic lymphoma: a comprehensive analysis of 114 cases.
Liu M; Liu B; Liu B; Wang Q; Ding L; Xia C; Dong L
Oncol Rep; 2015 Apr; 33(4):1615-20. PubMed ID: 25695332
[TBL] [Abstract][Full Text] [Related]
2. Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients.
Loghavi S; Alayed K; Aladily TN; Zuo Z; Ng SB; Tang G; Hu S; Yin CC; Miranda RN; Medeiros LJ; Khoury JD
J Hematol Oncol; 2015 Jun; 8():65. PubMed ID: 26055271
[TBL] [Abstract][Full Text] [Related]
3. Clinical and pathological aspects of human immunodeficiency virus-associated plasmablastic lymphoma: analysis of 24 cases.
Koizumi Y; Uehira T; Ota Y; Ogawa Y; Yajima K; Tanuma J; Yotsumoto M; Hagiwara S; Ikegaya S; Watanabe D; Minamiguchi H; Hodohara K; Murotani K; Mikamo H; Wada H; Ajisawa A; Shirasaka T; Nagai H; Kodama Y; Hishima T; Mochizuki M; Katano H; Okada S
Int J Hematol; 2016 Dec; 104(6):669-681. PubMed ID: 27604616
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic comparison of plasmablastic lymphoma in HIV-positive, immunocompetent, and posttransplant patients: single-center series of 25 cases and meta-analysis of 277 reported cases.
Morscio J; Dierickx D; Nijs J; Verhoef G; Bittoun E; Vanoeteren X; Wlodarska I; Sagaert X; Tousseyn T
Am J Surg Pathol; 2014 Jul; 38(7):875-86. PubMed ID: 24832164
[TBL] [Abstract][Full Text] [Related]
5. Extraoral plasmablastic lymphomas in a high human immunodeficiency virus endemic area.
Meer S; Perner Y; McAlpine ED; Willem P
Histopathology; 2020 Jan; 76(2):212-221. PubMed ID: 31361906
[TBL] [Abstract][Full Text] [Related]
6. Impact of the Epstein-Barr virus positivity on Hodgkin's lymphoma in a large cohort from a single institute in Korea.
Koh YW; Yoon DH; Suh C; Huh J
Ann Hematol; 2012 Sep; 91(9):1403-12. PubMed ID: 22526365
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological analysis of oral plasmablastic lymphoma: A systematic review.
Rodrigues-Fernandes CI; de Souza LL; Santos-Costa SFD; Silva AMB; Pontes HAR; Lopes MA; de Almeida OP; Brennan PA; Fonseca FP
J Oral Pathol Med; 2018 Nov; 47(10):915-922. PubMed ID: 29917262
[TBL] [Abstract][Full Text] [Related]
8. Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA group.
Tchernonog E; Faurie P; Coppo P; Monjanel H; Bonnet A; Algarte Génin M; Mercier M; Dupuis J; Bijou F; Herbaux C; Delmer A; Fabiani B; Besson C; Le Gouill S; Gyan E; Laurent C; Ghesquieres H; Cartron G
Ann Oncol; 2017 Apr; 28(4):843-848. PubMed ID: 28031174
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathologic features of plasmablastic lymphoma: Single-center series of 8 cases from Saudi Arabia.
Elyamany G; Alzahrani AM; Aljuboury M; Mogadem N; Rehan N; Alsuhaibani O; Alabdulaaly A; Al-Mussaed E; Elhag I; AlFiaar A
Diagn Pathol; 2015 Jun; 10():78. PubMed ID: 26108914
[TBL] [Abstract][Full Text] [Related]
10. Immune-checkpoint expression in Epstein-Barr virus positive and negative plasmablastic lymphoma: a clinical and pathological study in 82 patients.
Laurent C; Fabiani B; Do C; Tchernonog E; Cartron G; Gravelle P; Amara N; Malot S; Palisoc MM; Copie-Bergman C; Glehen AT; Copin MC; Brousset P; Pittaluga S; Jaffe ES; Coppo P
Haematologica; 2016 Aug; 101(8):976-84. PubMed ID: 27175027
[TBL] [Abstract][Full Text] [Related]
11. Durable remission is achievable with localized treatment and reduction of immunosuppression in limited stage EBV-related plasmablastic lymphoma.
Phipps C; Yeoh KW; Lee YS; Nagarajan C; Gopalakrishnan S; Ho LP; Hwang WYK; Goh YT; Grigoropoulos NF
Ann Hematol; 2017 Nov; 96(11):1959-1960. PubMed ID: 28831541
[No Abstract] [Full Text] [Related]
12. [Clinical features and outcomes: analysis of 9 cases of HIV-negtive plasmablastic lymphoma].
Gui L; He XH; Liu P; Yang JL; Qin Y; Zhou SY; Yang S; Zhang CG; Shi YK
Zhonghua Xue Ye Xue Za Zhi; 2016 Sep; 37(9):762-767. PubMed ID: 27719718
[TBL] [Abstract][Full Text] [Related]
13. Successful cord blood transplantation for an HIV-negative patient with refractory plasmablastic lymphoma.
Nishi K; Mitani S; Hatanaka K; Imada K
Ann Hematol; 2017 Jun; 96(6):1057-1058. PubMed ID: 28293711
[No Abstract] [Full Text] [Related]
14. Primary effusion lymphoma in Taiwan shows two distinctive clinicopathological subtypes with rare human immunodeficiency virus association.
Chen BJ; Wang RC; Ho CH; Yuan CT; Huang WT; Yang SF; Hsieh PP; Yung YC; Lin SY; Hsu CF; Su YZ; Kuo CC; Chuang SS
Histopathology; 2018 May; 72(6):930-944. PubMed ID: 29206290
[TBL] [Abstract][Full Text] [Related]
15. Plasmablastic lymphoma: An update.
Bailly J; Jenkins N; Chetty D; Mohamed Z; Verburgh ER; Opie JJ
Int J Lab Hematol; 2022 Sep; 44 Suppl 1(Suppl 1):54-63. PubMed ID: 36074710
[TBL] [Abstract][Full Text] [Related]
16. Post-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK/T cell lymphoma in the era of asparaginase.
Wang L; Wang H; Wang JH; Xia ZJ; Lu Y; Huang HQ; Jiang WQ; Zhang YJ
Oncotarget; 2015 Oct; 6(30):30317-26. PubMed ID: 26210287
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus and human immunodeficiency virus-negative oral plasmablastic lymphoma.
Lee OJ; Kim KW; Lee GK
J Oral Pathol Med; 2006 Jul; 35(6):382-4. PubMed ID: 16762021
[TBL] [Abstract][Full Text] [Related]
18. Dual Threat of Epstein-Barr Virus: an Autopsy Case Report of HIV-Positive Plasmablastic Lymphoma Complicating EBV-Associated Hemophagocytic Lymphohistiocytosis.
Koizumi Y; Imadome KI; Ota Y; Minamiguchi H; Kodama Y; Watanabe D; Mikamo H; Uehira T; Okada S; Shirasaka T
J Clin Immunol; 2018 May; 38(4):478-483. PubMed ID: 29687211
[TBL] [Abstract][Full Text] [Related]
19. A Case of Plasmablastic Lymphoma Achieving Complete Response and Durable Remission after Lenalidomide-Based Therapy.
Schmit JM; DeLaune J; Norkin M; Grosbach A
Oncol Res Treat; 2017; 40(1-2):46-48. PubMed ID: 28095384
[TBL] [Abstract][Full Text] [Related]
20. Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment.
Muti G; Cantoni S; Oreste P; Klersy C; Gini G; Rossi V; D'Avanzo G; Comoli P; Baldanti F; Montillo M; Nosari A; Morra E;
Haematologica; 2002 Jan; 87(1):67-77. PubMed ID: 11801467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
